Inogen reports recurring developments as a respiratory medical technology company serving homecare patients with chronic respiratory conditions. Its updates focus on financial results and outlook, portable oxygen concentrators, Simeox airway clearance, stationary oxygen concentrators, and Aurora CPAP masks for obstructive sleep apnea.
Company news also covers product introductions, clinical evidence and reimbursement work, international market activity, commercial partnerships, leadership and board changes, inducement equity awards, share repurchase actions, and investor conference participation.
Inogen (INGN) reported third-quarter 2026 revenue from continuing operations of $77.2 million, down from the prior-year period. Revenue fell 2.4%, while U.S. revenue rose 3.8%. Gross margin declined to 44.1% from 45.7%, and the loss from continuing operations widened to $14.8 million from $3.6 million.
Inogen completed its U.S. oxygen rental divestiture on November 2, 2026, for estimated cash consideration of up to $24.8 million. It initiated a cost program expected to generate approximately $20 million in annualized savings by the end of 2027 and increased its buyback authorization by $15 million to $45 million. Andy Reding was appointed president and CEO.
Inogen expects continuing-operations revenue of $65 million–$68 million for the fourth quarter and $298 million–$301 million for 2026, with a full-year adjusted loss of $7 million–$8 million. Cash and related holdings totaled $97.7 million, with no debt outstanding.
Inogen (Nasdaq: INGN) has appointed Chief Operating Officer Andy Reding as president, chief executive officer and a board member, succeeding Kevin Smith.
The board cited a need to improve performance as a reason for the transition. Reding joined Inogen as chief operating officer in July 2026 and has more than 30 years of medical technology experience. He previously served as chief commercial officer of Viant Medical and led Hillrom Respiratory Health.
Inogen will separately announce results for the third quarter ended September 30, 2026, and host an investor and analyst call on November 5 at 5:00 p.m. ET.
Inogen (Nasdaq: INGN) will report its third quarter 2026 financial results after the market closes on November 5, 2026. The company will host a conference call that day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. A live webcast and archived recording will be available through its Investor Relations website.
Inogen (INGN) signed a definitive agreement to sell its U.S. oxygen rental business to Rotech for estimated cash consideration of up to $25 million. Rotech will acquire specified rental assets, with closing expected in the fourth quarter of 2026. Inogen also signed a long-term supply agreement with Rotech.
Inogen expects the transactions to increase its revenue growth rate and adjusted operating income. Rental revenue was $24.3 million in the first half of 2026, down 9.8% year over year. Rental operations are expected to be presented as discontinued operations starting with third-quarter 2026 results, subject to final accounting analysis. The board approved a $15 million increase in share repurchase authorization to $45 million, subject to closing.
Inogen (Nasdaq: INGN) reported second quarter 2026 revenue of $95.1 million, up 3.0% year-over-year, driven mainly by 14.8% international sales growth to $41.3 million, while U.S. sales and rentals declined. GAAP net loss narrowed to $3.9 million, and adjusted EBITDA rose 15.2% to $2.4 million, with operating cash flow of $2.9 million.
Total gross margin was 45.5%, and cash, cash equivalents, marketable securities, and restricted cash totaled $106.8 million with no debt. The company raised 2026 adjusted EBITDA guidance to approximately $4.0 million and updated revenue guidance to $355–$361 million. Inogen highlighted the Canadian launch of the Rove 6 portable oxygen concentrator, publication of the QuOTE LTOT assessment tool, completion of Last Patient Last Visit in the Simeox H SCOPE study in China, and the appointment of a new COO. In the first half of 2026, Inogen repurchased 1,145,150 shares for $7.5 million.
Smartbird (NASDAQ: BIRD), an AI infrastructure provider, has nominated Elizabeth Mora and Dan Kasun for election to its board of directors at the next annual meeting of stockholders. Mora is a veteran finance and governance leader, former CFO of Draper Laboratory and Harvard University, and currently chair of the board at Inogen (NASDAQ: INGN), audit committee chair at MKS Instruments (NASDAQ: MKSI), and compensation and nominating and governance committee chair at Limoneira (NASDAQ: LMNR).
Kasun brings extensive AI, cloud, and channel sales experience from 18 years at Microsoft and 11 years at Amazon Web Services, and is senior vice president and global head of partner ecosystem at Pegasystems (NASDAQ: PEGA). According to Smartbird, these nominations align with its strategy to grow AI infrastructure-as-a-managed-service for enterprises in healthcare, pharma, financial services and the public sector, following the June appointment of Nadia Carlsten as president and CEO.
Inogen (Nasdaq: INGN) will report its second quarter 2026 financial results after market close on Thursday, August 6, 2026, followed by a conference call at 2:00 p.m. PT / 5:00 p.m. ET with live webcast and six‑month archive on its Investor Relations website.
Inogen (Nasdaq: INGN) appointed Andy Reding to the newly created role of Chief Operating Officer, effective July 6, 2026. He will drive revenue and operational performance, align cross-functional priorities, and support execution of Inogen’s strategy.
Reding has 30+ years of medtech leadership, including roles at Viant Medical and Hillrom Respiratory Health. As an inducement to join, he will receive 130,000 RSUs, vesting in three equal annual installments, approved under Nasdaq Listing Rule 5635(c)(4). Inogen will continue using its investor relations website to share material information and comply with Regulation FD.
Inogen (Nasdaq: INGN) reported Q1 2026 revenue of $85.1M, up 3.4% year-over-year, and reiterated full-year 2026 revenue guidance of $366M–$373M. GAAP net loss was $8.3M; adjusted net loss was $4.0M; adjusted EBITDA was -$1.4M. Cash and equivalents totaled $111.5M with no debt.
The company authorized a $30.0M share repurchase program, repurchased 298,100 shares for $1.9M, launched CPAP masks in the U.S., expanded internationally, and noted clinical and reimbursement trial progress.
Inogen (Nasdaq: INGN) will report first quarter 2026 financial results after market close on May 7, 2026 and host a conference call the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Live audio webcast, archived recording for six months, and a replay available through May 14, 2026 are accessible via the Inogen Investor Relations website. Dial-in and conference ID details are provided for live and replay access.